Drug intelligence / Profile preview

miR506-3p

Development stage
Preclinical
Lead developer
SiSaf
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

miR506-3p is a tumor-suppressive microRNA (the 3p arm of miR-506) that post-transcriptionally regulates multiple oncogenic pathways by binding complementary sites in target mRNA 3′UTRs and inducing mRNA degradation or translational repression. It is downregulated in several malignancies, including osteosarcoma, pancreatic ductal adenocarcinoma, ovarian cancer, liver cancer, lung cancer, and lung carcinoma, where its restoration via synthetic mimics or agomirs inhibits proliferation, invasion, metastasis, epithelial–mesenchymal transition, and promotes apoptosis, senescence, differentiation, and reactive oxygen species–mediated cell death.[1][3][4][5][6] Identified direct or functional targets include RAB3D and CDK4 in osteosarcoma, PIM-3 and multiple survival/autophagy regulators in pancreatic cancer, CDK4/6–FOXM1 and metastasis-related genes in ovarian cancer, MTMR6 and SIRT1 in liver or lung carcinoma, and a broader “targetome” of differentiation-modulating genes in neuroblastoma, making miR506-3p a candidate therapeutic agent for miRNA replacement or differentiation therapy using nanoparticle or agomir delivery systems.[1][3][4][5][6]

Other names
microRNA-506-3pmicroRNA506-3pmicroRNA 506-3pmiR-506-3pmiR506-3pmiR 506-3pmiRNA-506-3pmiRNA506-3pmiRNA 506-3pmiR506miR-506miR 506
02

Targets

JAG1 (Jagged-1 protein)MTMR6SPHK1 (Sphingosine kinase 1)EZH2 (Histone-lysine N-methyltransferase EZH2)RAB3D (Ras-related protein Rab-3D)RAD51 (RAD51 Recombinase)TULP3 (Tubby-related protein 3)SKP2ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on miR506-3p.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR506-3p.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call